Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 92
- Registration Number
- NCT00254137
Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 46
- Registration Number
- NCT00251407
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
- Conditions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 10
- Registration Number
- NCT00251797
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- First Posted Date
- 2005-11-04
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 6
- Registration Number
- NCT00248482
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT00233623
- Locations
- 🇮🇹
Research Center, Bari, Italy
🇮🇹Research Site, Venezia, Italy
Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00230399
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 23
- Registration Number
- NCT00217711
- Locations
- 🇨🇭
Hirslanden Klinik Aarau, Lausanne, Switzerland
🇨🇭City Hospital Triemli, Zurich, Switzerland
🇨🇭Kantonsspital Graubuenden, Chur, Switzerland
Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-11-25
- Target Recruit Count
- 24
- Registration Number
- NCT00215982
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇵🇷San Juan Veterans Hospital, Rio Piedras, Puerto Rico
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT00215501
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-01-13
- Target Recruit Count
- 21
- Registration Number
- NCT00215995
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇵🇷Ponce School of Medicine, Ponce, Puerto Rico
🇵🇷University of Puetro Rico Cancer Center, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.